The Promise of Stem Cells Reaching Patients
https://reachmd.com/programs/clinicians-roundtable/the-promise-of-stem-cells-reaching-patients/2971/
The promise of stem cell research, once deemed a scientists' dream, has turned the corner into real marketed products and looks to soon be a multi-billion-dollar industry. Randal Mills, the chief executive officer of Osiris Therapeutics tells the Chicago Tribune's Bruce Japsen about stem cell produc
Stem cells to regenerate the heart
https://reachmd.com/programs/clinicians-roundtable/stem-cells-to-regenerate-the-heart/2490/
A treatment that uses adult stem cells to rebuild failing hearts - once believed to be impossible - is making progress helping patients rebound from severe coronary artery disease, a leading killer of people around the world. Dr. Douglas Losordo, head of the program in cardiovascular regenerative me
Reprogamming Skin Cells to Act Like Stem Cells
https://reachmd.com/programs/clinicians-roundtable/reprogamming-skin-cells-to-act-like-stem-cells/2588/
Dr. Johnathan Moreno speaks with host Dr. Maurie Pickard about this year’s ground breaking research in the reprogramming of skin cells to act like stem cells. They also discuss the need for new embryonic cell lines that continue to be the gold standard. Continued progress in this area of research, h
Parsing the Debate Over Embryonic Stem Cells
https://reachmd.com/programs/clinicians-roundtable/parsing-the-debate-over-embryonic-stem-cells/2972/
While politicians debate whether there should be federal funding of embryonic stem cells, they might be over-looking a key point: the fact that all of the momentum in stem cell research is not in cells derived from human embryos at all. Randal Mills, the chief executive officer of Osiris Therapeutic
Stem Cell Therapy: A Major Regulatory Milestone
https://reachmd.com/programs/clinicians-roundtable/stem-cell-therapy-a-major-regulatory-milestone/2973/
2008 was a watershed year for stem cell-based treatment, with the first product of this kind going before an FDA review for approval. Learn more from Randal Mills, PhD, chief executive officer of Osiris Therapeutics, as he unveils details of his company’s stem cell-based medicine with host Bruce Jap
New Frontiers in Embryonic Stem Cell Research
https://reachmd.com/programs/clinicians-roundtable/new-frontiers-in-embryonic-stem-cell-research/4592/
President Obama expanded federal funding for certain embryonic stem cell research and many are excited about what it means to the entire field of discovery of new drugs and medical treatments. Linda Powers, of the Maryland Stem Cell Commission, tells host Bruce Japsen about the importance of Obama's
Stem Cell Research: The Mouse Incisor Model
https://reachmd.com/programs/clinicians-roundtable/stem-cell-research-the-mouse-incisor-model/2896/
Where do we stand with stem cell research, and what does the future hold for this controversial field of investigation? Host Dr. Bruce Bloom discusses stem cell research with Dr. Ophir Klein, of the Biomedical Sciences Graduate Program at the University of California, San Francisco.
Federal Funding Controversies and Stem Cell Research
https://reachmd.com/programs/clinicians-roundtable/federal-funding-controversies-and-stem-cell-research/4467/
The highly publicized decision by President Obama to add more federal dollars toward embryonic stem cell research may be fueling misconceptions about how drugs and medical products are created. But it's a part of the debate on stem cells that some in medicine think needs to be heard. Dr. Scott Gottl
Embryonic stem cell research chances
https://reachmd.com/programs/clinicians-roundtable/embryonic-stem-cell-research-chances/1588/
As political pressure builds on Republicans over the War in Iraq, will Congress finally OK a veto-proof bill to allow federal funding for embryonic stem cell research? Mary Woolley, CEO of Research America says the political climate is improving for a bill to pass and survive a Bush veto for embryon
Real Uses for Stem Cells On the Horizon
https://reachmd.com/programs/clinicians-roundtable/real-uses-for-stem-cells-on-the-horizon/4325/
Stem cells are often seen as potential agents in the field of regenerative medicine. What are the realities and what should doctors expect? Dr. Marc Hedrick, president of San Diego-based Cytori Therapeutics, tells the Chicago Tribune's Bruce Japsen about commercialized treatments already being used,